The DOI matches its Crossref record; 75 of the 77 references it cites were found in a registry or an index.
Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment
Open accessAbstract
Standard of care for cancer is commonly a combination of surgery with radiotherapy or chemoradiotherapy. However, in some advanced cancer patients this approach might still remaininefficient and may cause many side effects, including severe complications and even death. Oncolytic viruses exhibit different anti-cancer mechanisms compared with conventional therapies, allowing the possibility for improved effect in cancer therapy. Chemotherapeutics combined with oncolytic viruses exhibit stronger cytotoxic responses and oncolysis. Here, we have investigated the systemic delivery of the oncolytic adenovirus and paclitaxel encapsulated in extracellular vesicles (EV) formulation that, in vitro, significantly increased the transduction ratio and the infectious titer when compared with the virus and paclitaxel alone. We demonstrated that the obtained EV formulation reduced the in vivo tumor growth in animal xenograft model of human lung cancer. Indeed, we found that combined treatment of oncolytic adenovirus and paclitaxel encapsulated in EV has enhanced anticancer effects both in vitro and in vivo in lung cancer models. Transcriptomic comparison carried out on the explanted xenografts from the different treatment groups revealed that only 5.3% of the differentially expressed genes were overlapping indicating that a de novo genetic program is triggered by the presence of the encapsulated paclitaxel: this novel genetic program might be responsible of the observed enhanced antitumor effect. Our work provides a promising approach combining anticancer drugs and viral therapies by intravenous EV delivery as a strategy for the lung cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, Garofalo et al. showed lung tumor cell-derived exosomes can effectively carry the oncolytic virus and chemotherapeutic drugs (PTX), thus enhancing the antitumor effects in nude mice [57].”
From The Therapeutic Potential and Clinical Significance of Exosomes as Carriers of Drug Delivery System (2022) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Trapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,145
Biological properties of extracellular vesicles and their physiological functions
Yáñez‐Mó, M., Siljander, P. R. ‐., Andreu, Z., Bedina Zavec, A., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27066 · Cited by 5,926
Tumour exosome integrins determine organotropic metastasis
Hoshino, A., Costa-Silva, B., Shen, T.-L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., Molina, H., Kohsaka, S., Di Giannatale, A., Ceder, S., et al. (2015) · Nature · doi:10.1038/nature15756 · Cited by 5,101
Genesis: cluster analysis of microarray data
Sturn, A., Quackenbush, J., & Trajanoski, Z. (2002) · Bioinformatics · doi:10.1093/bioinformatics/18.1.207 · Cited by 1,761
Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper
Lener, T., Gimona, M., Aigner, L., Börger, V., Buzas, E., Camussi, G., Chaput, N., Chatterjee, D., Court, F. A., del Portillo, H. A., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.30087 · Cited by 1,491
Extracellular vesicles for drug delivery.
Vader, P., Mol, E. A., Pasterkamp, G., & Schiffelers, R. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.006 · Cited by 1,319
Exosomes/microvesicles as a mechanism of cell-to-cell communication
Camussi, G., Deregibus, M. C., Bruno, S., Cantaluppi, V., & Biancone, L. (2010) · Kidney International · doi:10.1038/ki.2010.278 · Cited by 1,200
Khuri, F. R., Nemunaitis, J. J., Ganly, I., Arseneau, J. C., Tannock, I. F., Romel, L., Gore, M. E., Ironside, J. A. D., MacDougall, R. H., Heise, C. C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,099
Lung cancer: Biology and treatment options
Lemjabbar‐Alaoui, H., Hassan, O. U., Yang, Y., & Buchanan, P. C. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.002 · Cited by 1,067
Alberg, A. J., & Samet, J. M. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4710-0.00046-8 · Cited by 1,058
Alberg, A. J., Brock, M. V., & Samet, J. M. (2003) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00052-x · Cited by 801
Oncolytic virus therapy: A new era of cancer treatment at dawn
Fukuhara, H., Ino, Y., & Todo, T. (2016) · Cancer Science · doi:10.1111/cas.13027 · Cited by 776
Exosomes maintain cellular homeostasis by excreting harmful DNA from cells
Takahashi, A., Okada, R., Nagao, K., Kawamata, Y., Hanyu, A., Yoshimoto, S., Takasugi, M., Watanabe, S., Kanemaki, M. T., Obuse, C., et al. (2017) · Nature Communications · doi:10.1038/ncomms15287 · Cited by 761
Albumin-bound paclitaxel: a next-generation taxane
Gradishar, W. J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1041 · Cited by 706
PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time
Kooijmans, S. A. A., Fliervoet, L. A. L., van der Meel, R., Fens, M. H. A. M., Heijnen, H. F. G., Henegouwen, P. M. P. V. B. E., Vader, P., & Schiffelers, R. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.009 · Cited by 645
Re-Engineering Extracellular Vesicles as Smart Nanoscale Therapeutics
Armstrong, J. P. K., Holme, M. N., & Stevens, M. M. (2017) · ACS Nano · doi:10.1021/acsnano.6b07607 · Cited by 616
Saari, H., Lázaro-Ibáñez, E., Viitala, T., Vuorimaa-Laukkanen, E., Siljander, P., & Yliperttula, M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.031 · Cited by 613
Self-citationHu, J. C. C., Coffin, R. S., Davis, C. J., Graham, N. J., Groves, N., GUEST, P. J., Harrington, K. J., James, N. D., Love, C., McNeish, I. A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0759 · Cited by 571
Delivery of chemotherapeutic drugs in tumour cell-derived microparticles
Tang, K., Zhang, Y., Zhang, H., Xu, P., Liu, J., Ma, J., Lv, M., Li, D., Katirai, F., Shen, G.-X., et al. (2012) · Nature Communications · doi:10.1038/ncomms2282 · Cited by 453
Extracellular vesicles: emerging targets for cancer therapy
Vader, P., Breakefield, X. O., & Wood, M. J. A. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.03.002 · Cited by 426
Exosomes as therapeutics: The implications of molecular composition and exosomal heterogeneity
Ferguson, S. W., & Nguyen, J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.037 · Cited by 420
Paclitaxel: What has been done and the challenges remain ahead
Bernabeu, E., Cagel, M., Lagomarsino, E., Moretton, M. A., & Chiappetta, D. A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.016 · Cited by 417
Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF
Koski, A., Kangasniemi, L., Escutenaire, S., Pesonen, S. A., Cerullo, V., Diaconu, I., Nokisalmi, P., Raki, M., Rajecki, M., Guse, K., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.161 · Cited by 243
Self-citationForget, P., Vandenhende, J., Berlière, M., Machiels, J., Nussbaum, B., Legrand, C., & Kock, M. D. (2010) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181d2ad07 · Cited by 233
Witwer, K. W., Soekmadji, C., Hill, A. F., Wauben, M. H. M., Buzás, E. I., Vizio, D. D., Falcón‐Pérez, J. M., Gardiner, C., Hochberg, F. H., Kurochkin, I. V., et al. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1396823 · Cited by 233
Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth.
Yokoyama, Y., Dhanabal, M., Griffioen, A. W., Sukhatme, V. P., & Ramakrishnan, S. (2000) · PubMed · Cited by 228
Jung, J., Mori, T., Kobayashi, C., Matsunaga, Y., Yoda, T., Feig, M., & Sugita, Y. (2015) · Wiley Interdisciplinary Reviews. Computational Molecular Science · doi:10.1002/wcms.1220 · Cited by 222
Intelligent Design: Combination Therapy With Oncolytic Viruses
Ottolino‐Perry, K., Diallo, J., Lichty, B. D., Bell, J. C., & McCart, J. A. (2009) · Molecular Therapy · doi:10.1038/mt.2009.283 · Cited by 211
Ranki, T., Pesonen, S. A., Hemminki, A., Partanen, K. P. L., Kairemo, K., Alanko, T., Lundin, J. E., Linder, N., Turkki, R., Ristimaki, A. P., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0121-5 · Cited by 204
Current Issues and Future Directions of Oncolytic Adenoviruses
Yamamoto, M., & Curiel, D. T. (2009) · Molecular Therapy · doi:10.1038/mt.2009.266 · Cited by 197
Deubiquitinase USP37 Is Activated by CDK2 to Antagonize APCCDH1 and Promote S Phase Entry
Huang, X., Summers, M. K., Pham, V. C., Lill, J. R., Liu, J., Lee, G., Kirkpatrick, D. S., Jackson, P. K., Fang, G., & Dixit, V. M. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.03.027 · Cited by 158
Focus on Extracellular Vesicles: Development of Extracellular Vesicle-Based Therapeutic Systems
Ohno, S., Drummen, G. P. C., & Kuroda, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020172 · Cited by 152
Gadgeel, S. M., Ramalingam, S. S., & Kalemkerian, G. P. (2012) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2012.06.003 · Cited by 144
Going viral: a review of replication-selective oncolytic adenoviruses
Larson, C., Oronsky, B. T., Scicinski, J. J., Fanger, G. R., Stirn, M., Oronsky, A. L., & Reid, T. R. (2015) · Oncotarget · doi:10.18632/oncotarget.5116 · Cited by 140
Rizvi, N. A., Riely, G. J., Azzoli, C. G., Miller, V. A., Ng, K., Fiore, J. J., Chia, G., Brower, M., Heelan, R. T., Hawkins, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8605 · Cited by 121
Toyoizumi, T., Mick, R., Abbas, A. E., Kang, E. H., Kaiser, L. R., & Molnar-Kimber, K. L. (1999) · Human Gene Therapy · doi:10.1089/10430349950016410 · Cited by 120
Oncolytic viruses: finally delivering
Seymour, L. W., & Fisher, K. D. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.481 · Cited by 118
Cancer Specific Viruses and the Development of ONYX-015
McCormick, F. P. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.216 · Cited by 106
Li, R., Xiaohua, T., Li, Y., Zhang, H., Ma, R., Ji, T., Dong, W., Tong, T., Liu, Y., Chen, D., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.02.025 · Cited by 101
Cerullo, V., Diaconu, I., Romano, V. C., Hirvinen, M., Ugolini, M., Escutenaire, S., Holm, L., Kipar, A., Kanerva, A., & Hemminki, A. (2012) · Molecular Therapy · doi:10.1038/mt.2012.137 · Cited by 97
Self-citationCapasso, C., Hirvinen, M., Garofalo, M., Romaniuk, D. S., Kuryk, Ł., Sarvela, T., Vitale, A., Antopolsky, M. L., Magarkar, A., Viitala, T., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1105429 · Cited by 87
Self-citationRecent advances in oncolytic adenovirus therapies for cancer
Shaw, A. R., & Suzuki, M. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.06.009 · Cited by 87
Enhanced Histopathology of the Immune System
Elmore, S. A. (2011) · Toxicologic Pathology · doi:10.1177/0192623311427571 · Cited by 84
DNA Polymerase ε: A Polymerase of Unusual Size (and Complexity)
Pursell, Z. F., & Kunkel, T. A. (2008) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(08)00004-4 · Cited by 79
Vile, R. G., Ando, D. G., & Kirn, D. H. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700548 · Cited by 77
Sze, D. Y., Reid, T. R., & Rose, S. C. (2013) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2013.05.040 · Cited by 66
Striking out at disseminated metastases: the systemic delivery of oncolytic viruses.
Fisher, K. (2006) · PubMed · Cited by 59
Extracellular vesicles – A promising avenue for the detection and treatment of infectious diseases?
Fuhrmann, G., Neuer, A. L., & Herrmann, I. K. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.04.005 · Cited by 59
Kuryk, Ł., Haavisto, E., Garofalo, M., Capasso, C., Hirvinen, M., Pesonen, S. A., Ranki, T., Vassilev, L., & Cerullo, V. (2016) · International Journal of Cancer · doi:10.1002/ijc.30228 · Cited by 57
Self-citationVassilev, L., Ranki, T., Joensuu, T. K., Jäger, E., Karbach, J., Wahle, C., Partanen, K. P. L., Kairemo, K., Alanko, T., Turkki, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1017702 · Cited by 56
Ingemarsdotter, C. K., Baird, S. K., Connell, C. M., Öberg, D., Halldén, G., & McNeish, I. A. (2010) · Oncogene · doi:10.1038/onc.2010.335 · Cited by 56
Mendez, N., Herrera, V., Zhang, L., Hedjran, F., Feuer, R., Blair, S. L., Trogler, W. C., Reid, T. R., & Kummel, A. C. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.08.010 · Cited by 55
Cheong, S. C., Wang, Y., Meng, J.-H., Hill, R., Sweeney, K. G., Kirn, D. H., Lemoine, N. R., & Halldén, G. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701099 · Cited by 53
Ranki, T., Joensuu, T. K., Jäger, E., Karbach, J., Wahle, C., Kairemo, K., Alanko, T., Partanen, K. P. L., Turkki, R., Linder, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.958937 · Cited by 49
Zhong, Z., Shi, S., Han, J., Zhang, Z., & Sun, X. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900151k · Cited by 44
Hassan, M. A., Braam, S. R., & Kruyt, F. A. E. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700984 · Cited by 44
Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity
Garofalo, M., Iovine, B., Kuryk, Ł., Capasso, C., Hirvinen, M., Vitale, A., Yliperttula, M. L., Bevilacqua, M. A., & Cerullo, V. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0559 · Cited by 44
Self-citationKuryk, Ł., Vassilev, L., Ranki, T., Hemminki, A., Karioja‐Kallio, A., Levälampi, O., Vuolanto, A., Cerullo, V., & Pesonen, S. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182715 · Cited by 40
Self-citationCerullo, V., Vähä-Koskela, M. J. V., & Hemminki, A. (2012) · OncoImmunology · doi:10.4161/onci.20172 · Cited by 34
Self-citationCai, X., Luo, J., Yang, X., Deng, H., Zhang, J., Li, S., Wei, H., Yang, C. Z., Xu, L., Jin, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4416 · Cited by 33
Oncolytic virotherapy: the questions and the promise
Aurelian, L. (2013) · Oncolytic Virotherapy · doi:10.2147/ov.s39609 · Cited by 29
Farzad, L., Cerullo, V., Yagyu, S., Bertin, T., Hemminki, A., Rooney, C. M., Lee, B., & Suzuki, M. (2014) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2014.8 · Cited by 29
Self-citationTso, K.-Y., Lee, S. D., Lo, K. W., & Yip, K. Y.-L. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-1172 · Cited by 26
Sharma, P., Kolawole, A. O., Wiltshire, S. M., Frondorf, K. A., & Excoffon, K. J. D. A. (2011) · Journal of General Virology · doi:10.1099/vir.0.036269-0 · Cited by 23
Intratumoral injection of taxol in vivo suppresses A549 tumor showing cytoplasmic vacuolization
Wang, C., & Chen, T. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24012 · Cited by 20
Niu, X. (2011) · Oncology Letters · doi:10.3892/ol.2011.334 · Cited by 20
Chen, H., Huang, X., Wang, S., Zheng, X., Lin, J., Li, P., & Lin, L. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.1000-9604.2014.12.17 · Cited by 19
Li, R., Wan, B., Zhou, J., Wang, Y., Luo, T., Gu, X., Chen, F., & Yu, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045932 · Cited by 18
Inactivation of Adenovirus Type 5 by Caustics
Jannat, R., Hsu, D. S., & Maheshwari, G. (2005) · Biotechnology Progress · doi:10.1021/bp049812f · Cited by 14
Xu, S., Tian, Y., Hu, Y., Zhang, N., Hu, S., Song, D., Wu, Z., Wang, Y., Cui, Y., & Tang, H. (2016) · Scientific Reports · doi:10.1038/srep28057 · Cited by 14
Weeklynab-Paclitaxel in Metastatic Breast Cancer – Summary and Results of an Expert Panel Discussion
Jackisch, C., Lück, H., Untch, M., Bischoff, J., Müller, V., Schmidt, M., Thill, M., & Kiechle, M. B. (2012) · Breast Care · doi:10.1159/000338273 · Cited by 7
Research works printed but not linked: 9
- Zhao, 2003, Adenovirus with insertion-mutated E1A selectively propagates in liver Cancer cells and destroys tumors in vivo advances in brief adenovirus with insertion-mutated E1A selectively propagates in liver Cancer cells and destroys tumors in vivo 1, Cancer Res., 3073
- Liebert, 1999, vol. 3029, 3013
- Eisenberg, 2007, 8, 603
- Rizvi, 2018, vol. 26, 639
- Chen, 2015, vol. 27, 190
- Bertoli, 2015, 14, 518
- Seymour, 2016, 114, 357
- Kooijmans, 2016, 224, 77
- Kim, 2017, HHS public, Access, 12, 655
Cited by
Sorted by citations
Advances and challenges in the treatment of lung cancer
Li, Y., Yan, B., & He, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115891 · Cited by 492
Oncolytic Viruses and the Immune System: The Dynamic Duo
de Matos, A. L., Franco, L. S., & McFadden, G. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.001 · Cited by 289
Preservation of biomaterials and cells by freeze-drying: Change of paradigm
Merivaara, A., Zini, J., Koivunotko, E., Valkonen, S., Korhonen, O., Fernandes, F. M., & Yliperttula, M. L. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.042 · Cited by 225
Self-citationExtracellular vesicles as a drug delivery system: A systematic review of preclinical studies
de Castilla, P. E. M., Tong, L., Huang, C., Sofias, A. M., Pastorin, G., Chen, X. S., Storm, G., Schiffelers, R. M., & Wang, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.011 · Cited by 219
Garofalo, M., Villa, A. M., Rizzi, N., Kuryk, Ł., Rinner, B., Cerullo, V., Yliperttula, M. L., Mazzaferro, V., & Ciana, P. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.022 · Cited by 138
Self-citation
Metadata
- Authors
- Garofalo, M., Saari, H., Somersalo, P., Crescenti, D., Kuryk, L., Aksela, L., Capasso, C., Madetoja, M., Koskinen, K., Oksanen, T., Mäkitie, A., Jalasvuori, M., Cerullo, V., Ciana, P., & Yliperttula, M.
- Affiliations
- University of Helsinki (FI)
- University of Milan (IT)
- University of Jyväskylä (FI)
- Corresponding author
- Garofalo, M.
- Yliperttula, M.
- ORCID
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 283
- Pages
- 223-234
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2806319473
- Cited by
- 138
- References
- 77
- Citations by year
- 2026: 5 · 2025: 16 · 2024: 18 · 2023: 18 · 2022: 17 · 2021: 22 · 2020: 28 · 2019: 9 · 2018: 5
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Controlled Release (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Työväentutkimus Vuosikirja (submittedVersion)
- Jyväskylä University Digital Archive (University of Jyväskylä) (submittedVersion, cc-by)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Funders
- Post doc pool foundation (016947-3)
- Italian Association for Cancer Research (IG-11903)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- oncolytic adenovirus, paclitaxel, extracellular vesicles, lung cancer, combination cancer therapy, intravenous drug delivery, xenograft tumor growth, gene expression profiling, differentially expressed genes, viral therapy
- MeSH terms
- Extracellular Vesicles, Animals, Antineoplastic Agents, Phytogenic, Combined Modality Therapy, Female, Humans, Liver, Lung Neoplasms, Mice, Inbred BALB C, Mice, Nude, Spleen, Paclitaxel, Cell Line, Tumor, Oncolytic Viruses
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
